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Summary
Multiple studies have consistently established that miR (microRNA)-210 induction is a feature of 
the hypoxic response in both normal and transformed cells. Here, we discuss the emerging 
biochemical functions of this miRNA and anticipate potential clinical applications. miR-210 is a 
robust target of hypoxia-inducible factor, and its overexpression has been detected in a variety of 
cardiovascular diseases and solid tumors. High levels of miR-210 have been linked to an in vivo 
hypoxic signature and associated with adverse prognosis in cancer patients. A wide spectrum of 
miR-210 targets have been identified, with roles in mitochondrial metabolism, angiogenesis, DNA 
repair, and cell survival. Such targets may broadly affect the evolution of tumors and other 
pathological settings, such as ischemic disorders. Harnessing the knowledge of miR-210’s actions 
may lead to novel diagnostic and therapeutic approaches.
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HYPOXIA-REGULATED NONCODING TRANSCRIPTS
Hypoxia is a hallmark of the neoplastic microenvironment and a well-documented source of 
therapeutic failure in clinical oncology (1). Low oxygen tension also plays a central role in 
the pathogenesis of major ischemic disorders, such as myocardial infarction, stroke, and 
peripheral artery disease (2); therefore, a deeper understanding of cellular adaptation to 
oxygen deprivation has broad and profound implications for translational medicine. 
Hypoxia-inducible factors (HIF) represent core components of the hypoxia-sensing 
machinery and orchestrate a regulatory transcriptional program comprising of hundreds of 
protein-encoding genes. Although historically gene induction by low oxygen, and in 
particular by HIF, has dominated hypoxia research, more recently the study of gene 
repression promoted by low oxygen tension has received increased attention (3, 4). Since 
2007 a multitude of reports demonstrated that specific microRNAs (miRNAs) are involved 
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in the hypoxic response and contribute to the repression of biologically important genes by 
low oxygen tension (5–11).
miRNAs act as regulators of most physiological and pathological cellular processes. In their 
mature active form, 19- to 24-ribonucleotides long, miRNAs are transferred to the RNA-
induced silencing complex (RISC), followed by base pairing to partially complementary 
sites, primarily within the 3′ untranslated regions (UTRs) of target genes. This generally 
leads to inhibition of target gene expression, by a combination of translational blockade 
and/or mRNA degradation. It is currently thought that thousands of classic (protein-
encoding) genes are regulated via such mechanisms (12). By virtue of interfering with 
multiple transcripts, often hundreds, miRNAs have the potential to regulate virtually all 
cellular mechanisms, such as differentiation, proliferation, death, and metabolism (13, 14).
miR-210’s ROLE IN CANCER
miR-210 is the only miRNA consistently upregulated in all published studies, in both 
normal and transformed hypoxic cells (5, 8–11, 15). It is also generally recognized as a 
robust HIF target (10, 16, 17), and its level may be a reflection of HIF activity even under 
circumstances of normoxic activation of this transcription factor. For example, miR-210 is 
particularly overexpressed in renal clear cell carcinomas (RCCs) (18), which express 
abnormally high levels of HIF, because of the genetic inactivation of the von Hippel-Lindau 
tumor suppressor, the well-recognized E3-ligase for HIF (19). Aside from the particular case 
of RCC, miR-210 is upregulated in most solid tumors and negatively affects the clinical 
outcome (8, 9, 20–24). Consistently, at least in breast cancer, miR-210 levels are correlated 
with a genetic signature of hypoxia, suggesting that tumor overexpression of this miRNA is 
the direct consequence of decreased oxygen tension in the microenvironment.
On the basis of the newly acquired knowledge of miR-210 targets and biochemical 
functions, we can begin to assess its involvement in human disease.
Mitochondrial Metabolism and Oxidative Stress
Following exposure to hypoxia, cell metabolism shifts from mitochondrial oxidative 
phosphorylation to glycolysis (often termed the “Pasteur effect”). This effect is generally 
thought to be a consequence of HIF activation, which in turn induces most glycolytic 
enzymes, pyruvate dehydrogenase kinase, and represses mitochondrial biogenesis (25). Very 
recent data from several groups have demonstrated that miR-210 contributes to this 
metabolic shift by downregulating several steps of mitochondrial metabolism and, in 
particular, the electron transport chain (ETC) complexes. Indeed, miR-210 directly represses 
the expression of iron-sulfur (Fe-S) cluster scaffold proteins, ISCU1 and ISCU2 (26–29). 
ISCU1/2 facilitates the assembly of Fe-S clusters that are incorporated into enzymes 
involved in energy production, including aconitase, which catalyses one step of the 
tricarboxylic acid cycle (TCA), as well as mitochondrial respiratory complexes I, II, and III 
(30). Other relevant mitochondrial miR-210 targets that have been reported are NADH 
dehydrogenase (ubiquinone) 1 alpha subcomplex 4 (NDUFA4) (9), a subunit of complex I, 
and succinate dehydrogenase complex, subunit D (SDHD), a subunit of complex II (31). An 
additional intriguing target is glycerol-3-phosphate dehydrogenase 1-like (GPD1-L) (27), 
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which may be involved in the Pasteur effect by modulating NAD+/NADH ratios (32). 
Although the biochemical function of GPD1L remains to be elucidated, it is highly 
homologous to glycerol-3-phosphate dehydrogenase (GPD), the catalyst of the glycerol 
phosphate shuttle, which transfers electrons from cytoplasmic NADH to the mitochondria 
electron transport chain. Thus, forced expression of miR-210 in normoxia represses 
mitochondrial respiration and enhances glycolysis, which leads to decreased ATP; therefore, 
it is not surprising that miR-210 presence is not beneficial when oxygen supply is optimal. 
In contrast, upon hypoxia, the repression of the electron transport chain decreases the 
mismatch with reduced oxygen tension increasing ATP levels (26), minimizing the impact 
of hypoxia on cell energy production. It is noteworthy that tumors largely rely on glycolysis 
even when the oxygen supply is normal (Warburg effect). In RCCs, miR-210 is high and the 
oxygen supply is also high compared with other solid tumors, as these are typically well-
vascularized tumors; therefore, miR-210 may be involved in a glycolytic shift in such 
tumors. Whether miR-210 is more generally involved in the Warburg effect is currently 
unclear.
The repressive effect of miR-210 on ETC also impacts on mitochondrial ROS production, 
an expected consequence of electron leakage. Indeed, miR-210 expression increases 
oxidative stress in normoxic conditions, and this is, at least in part, mediated by ISCU (26, 
28). However, conflicting results were reported in hypoxia. Favaro et al. (28), using cancer 
cell lines, described hypoxic induction of ROS and alleviation with anti-miR-210. On the 
other hand, Chan et al. (26), using normal endothelial cells, could not measure any 
significant change in ROS production after exposure to hypoxia, which increased when 
miR-210 was blocked. The reason for this discrepancy warrants additional investigation but 
may be a reflection of the underlying differences between normal versus cancer cells 
employed by the two studies.
Puissegur et al. (31) provided the first evidence that high miR-210 also contributes to 
maintenance of high HIF during hypoxia; therefore, miR-210 and HIF form a feed-forward 
loop. This mechanism may be dependent on the suppression of ISCU, SDHD, NDUFA4, 
and the resulting generation of ROS and TCA metabolites, such as succinate.
Collectively, these data demonstrate that miR-210 coordinates a metabolic shift in tumors 
toward a high glycolytic phenotype, which has been long thought to benefit tumor growth.
Tumors with high miR-210 may be particularly sensitive to antiglycolytic agents. In vitro, 
the first evidence was provided by Chen et al. (29). Cells overexpressing miR-210 were 
significantly more susceptible to killing by 3-bromo-pyruvate, an inhibitor of the glycolytic 
pathway. Molecules of this class, such as 2-deoxyglucose or dichloroacetate, have been 
considered as promising therapeutic agents; however, they are yet to fulfill their promise in 
clinical trials. Identification of molecular signatures of tumors that exhibit high sensitivity to 
such agents may help identify patients that could benefit from them, and a full understanding 
of miR-210’s role in this process may be a step in this direction.
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Angiogenesis
Given the role of hypoxia in angiogenesis induction, it is not surprising that hypoxia-
induced miR-210 seems to play a role in this event. We found that miR-210 overexpression 
in normoxic endothelial cells stimulated the formation of capillary-like structures as well as 
VEGF-driven cell migration. The direct involvement of this miRNA in these processes was 
demonstrated by the inhibition of both capillary-like structures formation and VEGF-
induced chemotaxis upon miR-210 blockade. One critical direct target of miR-210 
proangiogenic function is Ephrin-A3 (EFNA3) (10, 27). Override of its downmodulation 
either by miR-210 expression or by hypoxia prevents both tubulogenesis and chemotaxis 
stimulation. Further studies are ongoing to investigate the role of miR-210 in the stimulation 
of angiogenesis in vivo.
DNA Repair
Recent data indicate that miR-210 targets RAD52 (16, 27), which assists the loading of 
RAD51 onto DNA to form nucleoprotein filaments involved in homology-dependent repair 
(HDR) (33, 34). Previous work established that HDR activity is dramatically decreased in 
hypoxic cells (4, 35), and miR-210-mediated suppression of RAD52 may provide an 
additional mechanism by which HDR is suppressed in hypoxia. Whether miR-210’s action 
on RAD52 is enough to measurably affect DNA damage is currently unknown.
Regulation of Apoptosis
Compromised survival of cells devoid of miR-210 in severe hypoxia has been documented 
(10, 15, 28). However, the normoxic expression of miR-210 appears to be detrimental for 
cell viability, at least in some cell types. Mechanistically, recent evidence shows that 
miR-210 directly antagonizes an apoptotic component, CASP8AP2. The relevance of this 
for cancer is currently unknown, as the investigation was performed in the context of 
mesenchymal stem cell survival following ischemic preconditioning (36).
Cell Cycle
In contrast to other solid tumors, miR-210 is frequently underexpressed in ovarian cancers, 
which potentially leads to increased expression of E2F transcription factor 3 (E2F-3) (9). 
Likewise, miR-210 is also expressed at low levels in esophageal squamous cell carcinomas, 
derepressing fibroblast growth factor receptor-like 1 that in turn accelerates cell cycle 
progression (37).
However, one cannot generally state that miR-210 induction in hypoxia negatively regulates 
cell cycle progression. miR-210 overexpression in cancer cell lines bypassed hypoxia-
induced cell cycle arrest and partially reversed the hypoxic gene expression signature (38). 
In these particular cells, miR-210 activates the myc pathway, via downregulation of the c-
Myc antagonist MNT, and loss of MYC abolished miR-210-mediated override of hypoxia-
induced cell cycle arrest. Therefore, the net impact of miR-210 on cell proliferation seems to 
be context dependent.
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miR-210’s ROLE IN CEREBROVASCULAR AND CARDIOVASCULAR 
DISEASES
The significance of HIF regulation of miR-210 is not limited to cancer, as hypoxia is a 
central component of other clinical conditions, which have major impacts on morbidity and 
mortality, including cardiac and peripheral ischemia as well as cerebrovascular diseases (2).
Although further work is needed to substantiate a mechanistic role in such disorders, 
miR-210 was reported to be upregulated in animal models of cardiac hypertrophy, heart 
failure (39, 40), transient focal ischemia in the brain (41), hindlimb ischemia (11, 41), and in 
ischemic wounds (42). miR-210 is also induced in the corresponding clinical settings: acute 
myocardial infarction (43), atherosclerosis obliterans (44), and preeclampsia (45–47). 
Consistently, select miR-210 targets, and in particular GPD1L and ISCU, exhibit a 
significant role in cardiovascular biology. GPD1L mutations are associated with a subset of 
sudden infant cardiac death patients and with certain cases of Brugada syndrome, a disease 
that induces syncope, ventricular arrhythmias, and sudden death (48, 49). ISCU mutations, 
on the other hand, are associated with hereditary lactic acidosis, characterized by myopathy 
and exercise intolerance (50).
In the brain, miR-210 has been linked to the regulation of EFNA3 and neuronal pentraxin 1 
(NP1) in the central nervous system (11). As NP1 stimulates ischemic cell death, its 
experimentally confirmed downregulation by miR-210 during hypoxia and ischemia may be 
part of a survival mechanism in stroke. Contrary to the expectation of miRNA-mediated 
repression, EFNA3 was expressed at high levels in postischemic mouse hippocampus, 
exhibiting a similar trend to miR-210 (11). Although a series of possible explanations may 
be hypothesized, it is worth noting that EFNA3 transcription is induced by hypoxia (10). 
Thus, EFNA3 protein levels are determined by the balance of mRNA induction and miRNA 
repression, and hence, the outcome may change in different pathological contexts.
Preeclampsia is another example of a disorder with a tissue hypoxic component (45). 
Consistently, miR-210 was found upregulated in these placentas when compared with those 
of normal pregnant women. (47). However, at this stage, the association is mostly 
correlative, and a mechanistic involvement of miR-210 in this condition has not been 
determined (46).
miR-210 experimentally validated targets and their potential regulatory functions are 
summarized in Fig. 1.
IS THE END IN SIGHT FOR miR-210 TARGETS?
A comprehensive understanding of the biological and biochemical roles of miR-210 in 
hypoxia requires a complete knowledge of its targets; however, the search for targets 
remains the bottleneck of miRNA research. A continuously increasing number of target 
identification algorithms have been developed, such as PicTar, TargetScan, DianaLab, 
micro-RNA.org, and MicroCosm (51).
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For miR-210, such an in silico search reveals a dauntingly complex spectrum of candidate 
targets, including genes involved in proliferation, DNA repair, chromatin remodeling, 
metabolism, and cell migration (8–11, 16, 26, 29, 52, 53). Most of these programs search for 
complementarity between the miRNA “seed” sequences and the 3′ UTR of all known genes, 
and the resulting set of candidates generally contains hundreds of genes. Moreover, when 
the search is extended to the 5′ UTR and the coding region, the number is even higher. On 
the other hand, it is becoming increasingly apparent that “seed” binding is not necessarily 
sufficient, as other features of the surrounding sequences can affect binding efficacy. No 
specific algorithm is generally acknowledged as the most sensitive or accurate, and to 
further complicate matters, the lists of candidates generated by these different algorithms 
usually exhibit very limited overlap. Finally, relying on one particular program may well 
lead to missing most targets. For example, PicTar and TargetScan predict relatively few 
targets for human miR-210, and most of the experimentally validated targets are not 
predicted by any of these programs. Such difficulties prompted the use of integrated 
bioinformatic and experimental approaches to identify relevant miR-210 targets. One widely 
used approach takes advantage of the ability of many miRNAs to induce target mRNA 
destabilization. Gene expression is measured in the whole transcriptome or for a subset of 
genes in cells where a specific miRNA is either overexpressed or knocked down. Then, only 
those transcripts modulated in the expected direction are further analyzed with target 
prediction software programs to distinguish between direct and indirect targets. For instance, 
both Zhang et al. (38) and Puissegur et al. (31) began their search by identifying transcripts 
that were downmodulated upon forced miR-210 expression in colorectal and lung 
adenocarcinoma cancer cell lines, respectively. The downregulated genes that also contained 
a predicted miR-210-binding site were analyzed further to confirm the identity of MNT (38), 
NDUFA4, and SDHD (31) as bona fide targets.
Alternative approaches were based on direct analysis of the mRNAs associated with the 
RISC complex. Our group used a combination of proteomic and transcriptomic techniques 
to identify miR-210-modulated genes (27). Specifically, proteomic profiling of human 
primary endothelial cells identified at least 10 downmodulated proteins in miR-210-
expressing cells. In additional experiments, 52 transcripts were found to be both induced 
upon miR-210 knockdown and downmodulated by miR-210 expression. Very few, if any of 
these genes were found by target identification algorithms. However, a low stringency 
search revealed that these genes were enriched in miR-210 seed-complementary sequences. 
Analysis of the mRNAs associated with the RISC loaded with miR-210 and purified by 
immunoprecipitation revealed that the complex was significantly enriched for 16 candidate 
targets. Intriguingly, the seed matches for nine of these genes were localized in the 5′ UTR 
or in the coding region. Furthermore, a noncoding RNA involved in the epigenetic 
inactivation of the X chromosome (Xist) was identified in the RISC immunoprecipitate, 
revealing a previously unsuspected layer of interaction between noncoding RNAs. Finally, 
15 targets predicted by Pictar and TargetScan were also validated in our study, underlining 
the usefulness of such programs, especially in conjunction with additional experimental 
approaches.
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Using a similar strategy, Huang et al. (54) compared RISC immunoprecipitates of normoxic 
and hypoxic breast cancer cells. This resulted in the identification of more than 200 mRNAs 
that were enriched following cell exposure to hypoxia. In silico search revealed that 50 of 
these were recognized as direct miR-210 targets by prediction software, and a subset of 
these genes was further validated by independent techniques.
As expected, because of the clear differences in the above two experimental approaches, 
there are very few targets in common. However, this may not be surprising because the 
number of identified targets is still limited, whereas computational predictions estimate that 
each miRNA can target, on an average, more than 200 genes.
Quo Vadis, miR-210?
The question remains whether miR-210 will ultimately have an exclusive impact on 
diagnosis or it may also emerge as a therapeutic target. Recent development of anti-miRNA 
agents such as locked nucleic acid probes (LNAs) represents significant steps for therapeutic 
targeting of onco-miRNAs (55, 56). It is conceivable that inactivation of a miRNA involved 
in hypoxic adaptation would be a viable strategy to target a tumor compartment that poses 
significant therapeutic challenges. From a diagnostic standpoint, it was recently shown that 
miR-210 is increased in the serum from patients with diffuse large B-cell lymphoma (24) 
and in the plasma of pancreatic cancer patients (57, 58). Thus, quantification of miR-210 
may be further developed into clinical assays to provide valuable information about tumor 
biology and help guide therapeutic decisions.
Based on its prosurvival and proangiogenic roles, miR-210 may also be therapeutically 
relevant in cardiovascular diseases. Preclinical work showed that intracardiac injections with 
a minicircle vector carrying miR-210 in a mouse model of myocardial infarction induced 
significant improvement of left ventricular fractional shortening, decreased cellular 
apoptosis, and increased neovascularization (59).
Another major unanswered question is whether HIF is the only regulator of miR-210. If the 
history of gene regulation has taught us anything, the likely answer will turn out to be “no,” 
although direct evidence for additional players is currently missing. In our own experience, 
growth factor deprivation, osmotic stress, acidosis, and oxidative stress did not elicit 
miR-210 induction (10) (Kulshreshtha and Ivan, unpublished). However, we noticed the 
presence of multiple conserved transcription factor recognition sites in the vicinity of 
miR-210 genomic region: Oct-4, AP2, PPARc, and E2F (60). Interestingly, Oct-4 is itself a 
hypoxia-regulated gene (61) and may add an additional layer of complexity to miR-210 
regulation. As a concluding thought, miR-210 has emerged as a nodal molecular component 
linking microenvironment, metabolism, and clinical course in cancer, the first such case to 
our knowledge.
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Figure 1. 
Hypoxia regulates miR-210, which in turn mediates the expression of factors that are 
implicated in various physiopathological pathways.
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